Charles Schwab Investment Management Inc. Grows Stock Position in Phreesia, Inc. $PHR

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Phreesia, Inc. by 5.9% in Q1, now owning 522,384 shares valued at approximately $13.35 million.
• Institutional investors own a significant 92.10% of Phreesia's stock, with other firms such as Deutsche Bank AG and CWM LLC also increasing their holdings.
• Phreesia reported a revenue increase of 14.5% year over year, with earnings per share of ($0.07), exceeding consensus estimates for the quarter.

Charles Schwab Investment Management Inc. boosted its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 5.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 522,384 shares of the company's stock after buying an additional 28,936 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.89% of Phreesia worth $13,352,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of PHR. Vanguard Group Inc. grew its position in Phreesia by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock worth $126,177,000 after purchasing an additional 113,405 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in Phreesia by 133.6% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock valued at $31,999,000 after purchasing an additional 727,384 shares during the last quarter. Millennium Management LLC lifted its holdings in Phreesia by 83.2% during the 4th quarter. Millennium Management LLC now owns 653,634 shares of the company's stock valued at $16,445,000 after purchasing an additional 296,863 shares during the last quarter. Northern Trust Corp raised its stake in shares of Phreesia by 6.6% in the fourth quarter. Northern Trust Corp now owns 571,807 shares of the company's stock worth $14,387,000 after acquiring an additional 35,392 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its stake in shares of Phreesia by 41.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 484,617 shares of the company's stock worth $12,193,000 after acquiring an additional 141,411 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Phreesia news, insider David Linetsky sold 17,445 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $29.73, for a total value of $518,639.85. Following the completion of the sale, the insider directly owned 174,002 shares in the company, valued at approximately $5,173,079.46. This represents a 9.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Evan Roberts sold 1,892 shares of the company's stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total value of $50,875.88. Following the sale, the chief operating officer owned 772,915 shares of the company's stock, valued at $20,783,684.35. This trade represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,327 shares of company stock worth $2,031,647. Insiders own 5.50% of the company's stock.

Phreesia Stock Performance

Shares of Phreesia stock traded up $0.56 during trading on Thursday, hitting $32.55. 522,457 shares of the company's stock traded hands, compared to its average volume of 534,121. The stock has a market capitalization of $1.94 billion, a P/E ratio of -43.98 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. The business has a 50-day simple moving average of $27.81 and a 200-day simple moving average of $26.47. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The firm had revenue of $115.94 million for the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.The business's quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS. As a group, analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PHR shares. Canaccord Genuity Group reduced their price target on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th. KeyCorp increased their price objective on shares of Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Citigroup reiterated a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. DA Davidson upgraded shares of Phreesia to a "strong-buy" rating in a report on Tuesday, July 22nd. Finally, Mizuho started coverage on shares of Phreesia in a research report on Wednesday. They issued an "outperform" rating and a $36.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.58.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.